The effects of osteoprotegerin on the mechanical properties of rat bone.
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a naturally secreted protein that decreases bone resorption by inhibiting osteoclast differentiation and activation while promoting osteoclast apoptosis [8]. In this study, the effects of osteoprotegerin injections on long bone mechanical and material properties were investigated in young male Sprague-Dawley rats. OPG increased fracture strength at the femur mid-diaphysis in three-point bending by 30%, without affecting the elastic or maximum strength. At the femoral neck, OPG significantly increased the elastic (45%), maximum (15%), and fracture (35%) strengths. There was not a difference in microhardness at the femur mid-diaphysis in comparing the placebo and OPG groups. There were, however, significant increases in whole bone dry mass (25%), mineral mass (30%), organic mass (17%), and percent mineralization (4%); percent mineralization at the mid-diaphysis (3%); and percent mineralization at the distal epiphysis (6%) due to the OPG treatment. While OPG decreased endocortical bone formation (52%), total bone area, endocortical bone area, and periosteal bone formation were maintained with OPG treatment. A 30% increase in the X-ray opacity of the bone at the proximal metaphysis of the right tibiae was observed. Overall, OPG increased mineralization and strength indices in the rat femur. Its effects on strength were more pronounced in the femoral neck than at the mid-diaphysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“OPG had no influence on longitudinal bone growth in normal young rats (185), mice (186), piglets (187), or cynomolgus monkeys (25).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [185]
In the citing paper
“OPG treatment of normal rats was shown to increase matrix mineralization and improve bone strength (185).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [185]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationParfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187
Self-citationHardness, Young's modulus and yield stress in mammalian mineralized tissues
Currey, J. D., & Brear, K. (1990) · Journal of Materials Science Materials in Medicine · doi:10.1007/bf00705348 · Cited by 150
Effects of Rehydration State on the Flexural Properties of Whole Mouse Long Bones
Broz, J. J., Simske, S. J., Greenberg, A. R., & Luttges, M. W. (1993) · Journal of Biomechanical Engineering · doi:10.1115/1.2895510 · Cited by 84
Self-citationOsteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66
Self-citation
Research works printed but not linked: 1
- M. Yamamoto, T. Murakami, M. Nishikawa, E. Tsuda, S. Mochizuke, K. Higashio, T. Akatsu, K. Motoyoshi and N. Nagata, Endocrinology 139 (1998) 4012. · doi:10.1210/endo.139.9.6290 · Paper page
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationKostenuik, P. J., Nguyen, H. Q., McCabe, J., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R. C., Van, G., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 443
Self-citationEffects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Self-citationOminsky, M. S., Li, X., Asuncion, F. J., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M., Tan, H.-L., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 131
“Whereas OPG has been shown to improve femur neck strength in gonad-intact rats,((25)) there are no published data describing the effects of RANKL inhibition on femur neck strength under conditions of estrogen ablation.”
BackgroundSelf-citationDelmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 129
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.022 · Cited by 110
Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103
“The pharmacologic potential of OPG was first demonstrated by the ability of recombinant OPG (rOPG) to increase bone density((7)) and strength((16)) in rodents.”
BackgroundSelf-citationDempster, D. W., Brown, J. P., Fahrleitner‐Pammer, A., Kendler, D. L., Rizzo, S., Valter, I., Wagman, R. B., Yin, X., Yue, S. V., & Boivin, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02669 · Cited by 99
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.04.023 · Cited by 95
Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q., Asuncion, F., Tan, H., Grisanti, M. S., Dwyer, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.06.011 · Cited by 69
“This phenomenon might not be unique to ORX rats, as OPG-Fc treatment of young, gonad-intact male rats was previously shown to increase periosteal mineralizing surface and periosteal bone formation rate parameters by 36% and 60%, respectively [54].”
BackgroundSelf-citationDenosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
Sharp, J. T., Tsuji, W. H., Ory, P. A., Harper-Barek, C., Wang, H., & Newmark, R. (2010) · Arthritis Care & Research · doi:10.1002/acr.20172 · Cited by 67
RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 63
“In young male rats, RANKL inhibition increases bone mineralisation and improves mechanical strength in the femur [49].”
BackgroundOminsky, M. S., Kostenuik, P. J., Cranmer, P., Smith, S. Y., & Atkinson, J. E. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0363-7 · Cited by 55
“Although this surrogate of bone strength has not been validated in primate species, other studies in rats have shown significant improvements in actual bone strength with OPG treatment, including increases in the strength of the femoral neck [12] and diaphysis [12, 13].”
BackgroundSelf-citationSamelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 49
“However, our findings are consistent with animal models reporting that recombinant OPG increased periosteal circumference of the femoral neck in rats and the proximal tibia and distal radius in monkeys (7, 10).”
ResultOminsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 45
Self-citationSafety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 41
“In young male rats, RANKL inhibition increases bone mineralization and improves mechanical strength in the femur.(26) These preclinical studies and others with similar findings paved the way for the study of RANKL inhibition in humans.”
Clinical utility of denosumab for treatment of bone loss in men and women
Adler, R. A., & Gill, R. S. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s14565 · Cited by 37
Denosumab: recent update in postmenopausal osteoporosis.
da Silva, I. S., & Branco, J. (2012) · PubMed · Cited by 35
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 37
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Morony, S., Adamu, S., Simionescu, D. T., Basalyga, D. M., Asuncion, F., & Bateman, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0509-7 · Cited by 33
“The proximal portions were embedded vertically in noninfiltrating Epo-Kwick epoxy (Buehler, Lake Bluff, IL) from the mid-trochanter to 2 mm distal to the base of the femoral neck [34].”
MethodSelf-citationSzulc, P., Hawa, G., Boutroy, S., Vilayphiou, N., Schoppet, M., Chapurlat, R. D., & Hofbauer, L. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2617 · Cited by 26
Appropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
“Further, animal studies demonstrated that inhibition of RANKL increases trabecular and cortical bone mass and strength, while its overexpression causes an osteoporotic phenotype characterized by high bone resorption [57,58].”
BackgroundAuthentication of Oviductus Ranae and Its Original Animals Using Molecular Marker.
Xuegan, Y., Yi-quan, W., Kaiya, Z., & Zhong-quan, L. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1035 · Cited by 15
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Lewiecki, E. M. (2006) · Women s Health · doi:10.2217/17455057.2.4.517 · Cited by 12
“In young male rats, RANKL inhibition has been shown to increase bone mineralization and improve mechanical strength in the femur [40].”
BackgroundBonnet, N., Gerbaix, M., Ominsky, M. S., Ammann, P., Kostenuik, P. J., & Ferrari, S. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0124-8 · Cited by 9
“Moreover, as reported in bone repair models, we observed a larger callus volume after RANKL inhibition, probably due to the inhibition of the callus remodeling process [21, 36].”
BackgroundSelf-citationGaraicoa‐Pazmiño, C., Decker, A. M., & Polverini, P. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23297-3_8 · Cited by 8
Antibodies for the Treatment of Bone Diseases: Preclinical Data
Sipos, W. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_9 · Cited by 4
Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung
Trubrich, A., Kocijan, R., Muschitz, C., & Resch, H. (2011) · Osteologie/Osteology · doi:10.1055/s-0037-1619994 · Cited by 3
“Das trabekuläre Knochenvolumen dieser Tiere ist um ca. 50 % höher und die Knochenfestigkeit signifikant erhöht.”
BackgroundRANK/RANK-Ligand/OPG: Ein neuer Therapieansatz in der Osteoporosebehandlung
Preisinger, E. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 6
Payne, K. A., Shaw, N. M., Erickson, C. B., Yarger, P., Yu, Y., Baldini, T. H., Kleck, C. J., Patel, V. V., & Burger, E. L. (2022) · Spine · doi:10.1097/brs.0000000000004412 · Cited by 3
RANKL Inhibition: Preclinical Data
Sipos, W. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0520-7_9 · Cited by 2
“of bone fracture strength at the femur mid-diaphysis in three-point bending by 30 % without affecting elastic or maximum strength in young male Sprague-Dawley rats (Ross et al. 2001).”
BackgroundThe differential effects of two critical osteoclastogenesis stimulating factors on bone biomechanics
Yuan, Y. (2007) · TigerPrints (Clemson University) · Cited by 1
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc197
Osteoporosis and sarcopenia in older adults
Chalhoub, D. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Kendler, D. L. (2010) · Orthopedic Research and Reviews · doi:10.2147/orr.s6124
“61 68 In almost all diseases associated with excessively high rates of bone resorption, the RANK–RANKL pathway has been demonstrated to play a crucial role in the recruitment and activation of osteoclasts, leading to significant, rapid losses in bone mass: osteoporosis, 69–71 Paget’s disease, 72…”
A pharmacodynamic investigation into the efficacy of osteoprotegerin during aseptic inflammation
Curl, L., Barker, C., Dreyer, C. W., & Sampson, W. J. (2012) · Australasian Orthodontic Journal · doi:10.2478/aoj-2012-0020
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc197.pub2 · Cited by 1
Echtler, S. (2014) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17260
Metadata
- Authors
- Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J.
- Affiliations
- University of Colorado Boulder (US)
- Amgen (United States) (US)
- Corresponding author
- Bateman, Ted A.
- Venue
- Journal of Materials Science: Materials in Medicine
- Published
- 2001-07
- Volume
- 12
- Issue
- 7
- Pages
- 583-588
- ISSN
- 0957-4530 (ISSN-L)
- 1573-4838
- OpenAlex
- W194340635
- Cited by
- 39
- References
- 12
- Citations by year
- 2022: 1 · 2021: 1 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2012: 3
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Materials Science Materials in Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Aeronautics and Space Administration
- Amgen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Keywords
- osteoprotegerin, bone mechanical properties, bone mineralization, bone strength, femoral neck, femoral diaphysis, bone mineral mass, bone formation, bone resorption, three-point bending, microhardness, X-ray opacity, rat femur
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.